Swedish pharma company developing long-acting injectable drugs for opioid dependence and pain, using its FluidCrystal delivery technology.
Swedish pharma company developing long-acting injectable drugs for opioid dependence and pain, using its FluidCrystal delivery technology.
Sells a weekly or monthly buprenorphine injection, marketed as Buvidal in Europe and Australia and as Brixadi in the US, for opioid dependence. It also earns milestone and licence payments when other drug makers use its FluidCrystal delivery technology for their own products.
In one line: A specialty drug-delivery pharma like a smaller Indivior.
Moat: narrow (IP / patents, process know-how). Proprietary lipid-based depot delivery technology and patents on approved long-acting injectables.
Headquarters: Lund, Sweden · Founded: 1993 · Employees: 285
Size Camurus (CAMX.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $4.36B, the 50th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 732.50 on 18 Nov 2026.
Performance Over six months the shares gained 36.0%, against +0.8% for the median peer and +2.8% for the Sweden market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 3.0% over the last twelve months (peer median +10.2%); the operating margin is 38.4% (peer median 15.7%).
Valuation It trades at 45.1× forward earnings against a peer median of 29.9× (most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +46%, so the hurdle is -39 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 96.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 2.42B | SEK 2.27B | SEK 1.87B | SEK 1.72B | SEK 956M |
| Revenue growth | — | +21% | +9% | +80% | — |
| Gross profit | SEK 2.23B | SEK 2.10B | SEK 1.74B | SEK 1.59B | SEK 850M |
| EBITDA | SEK 958M | SEK 907M | SEK 484M | SEK 544M | SEK 83.5M |
| Net income | SEK 756M | SEK 736M | SEK 428M | SEK 431M | SEK 55.6M |
| Free cash flow | SEK 810M | SEK 731M | SEK 360M | SEK 598M | SEK 99.3M |
| Capital expenditure | SEK 167M | SEK 139M | SEK 29.4M | SEK 10.1M | SEK 1.91M |
| Total debt | SEK 107M | SEK 106M | SEK 17.0M | SEK 24.5M | SEK 26.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Camurus CAMX.ST | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% |
| Alkermes Public ALKS | $7.87B | +27% | +15% | 5% | n/a | 32.5% |
| Ipsen IPN.PA | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% |
| Crinetics Pharmaceuticals CRNX | n/a | +109% | n/a | n/a | n/a | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 17.5× | 1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CAMX.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.3% | -2.9% | 6th highest of 21 |
| 6-month return | +36.0% | +0.8% | 3rd highest of 20 |
| Distance from 52-week high | -2.3% | -32.7% | 2nd highest of 21 |
| Revenue growth (TTM) | +3.0% | +10.2% | 8th lowest of 19 |
| Operating margin | 38.4% | 15.7% | 2nd highest of 19 |
| Forward P/E | 45.1× | 29.9× | most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 7.9% | 5.7% | 8th most demanding of 17 |
| Growth delivered (Del g) | +46.5% | +8.6% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -38.5 pp | -3.7 pp | 3rd least demanding of 17 |
| ROIC minus cost of capital | +96.6 pp | +4.9 pp | highest of 18 |
| EV / EBITDA | 41.9× | 21.5× | 2nd most expensive of 11 |
| Net debt / EBITDA | -4.4× | -0.5× | 3rd least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.45B | -13% | +1% | 3% | 12.9× | -0.7% | +4.7% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |